Title:The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab
in Solid Tumors
Volume: 24
Issue: 7
Author(s): Mengmeng Chen, Jian Jiang, Junyu Chen, Mengqi Wang, Yaci Lu, Lei Liu, Lijing Zhao*Lisheng Wang*
Affiliation:
- Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 130021, China
- Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 130021, China
Keywords:
PD-L1 antibody, safety, therapy efficacy, solid tumors, durvalumab, inhibitors.
Abstract: Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint
inhibitors have been on the front line of clinical revolution in which, the targeted PD-L1 therapy
has obtained some success in patients with solid tumors. A large number of clinical trials revealed
that both monotherapy and combination therapy of PD-L1 antibody significantly suppress
some tumor growth and promote the survival of patients. At present, anti-PD-L1 treatment has
been used as a portion of standard treatment for lung cancer, breast cancer, head and neck squamous
cell carcinoma, and urothelial carcinoma. Although much evidence has demonstrated that
PD-L1 antibody is safe in most patients, there are still some adverse reactions, such as pneumonitis,
hepatitis, colitis, neurologic events and myocarditis. In this review, the clinical information, including
the efficacy and safety of durvalumab in solid tumors, was enumerated and summarized at
this stage to grasp the current application of targeted PD-L1 therapy and provide guidance for clinical
application.
